Polymer Capital Management US LLC Purchases New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

Polymer Capital Management US LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 15,755 shares of the company's stock, valued at approximately $381,000.

Other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. boosted its holdings in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. grew its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,287 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total transaction of $798,976.97. Following the transaction, the insider now directly owns 209,661 shares of the company's stock, valued at approximately $7,193,468.91. The trade was a 10.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 54,153 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the completion of the transaction, the insider now owns 165,650 shares of the company's stock, valued at $4,952,935. This trade represents a 24.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 835,884 shares of company stock worth $31,659,701. 17.71% of the stock is currently owned by company insiders.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Truist Financial lowered their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Finally, Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $38.25.

Hims & Hers Health Stock Up 1.2 %

Shares of HIMS traded up $0.32 during trading hours on Friday, hitting $27.13. The company had a trading volume of 16,210,541 shares, compared to its average volume of 15,146,132. The firm has a market cap of $6.03 billion, a P/E ratio of 61.66 and a beta of 1.65. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The stock's 50 day moving average price is $38.75 and its 200 day moving average price is $30.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.